autoimmunity inhibitor

JAK2/STAT3-IN-1 是一种 GP130 抑制剂，具有抗肿瘤作用，可用研究炎症，自身免疫和癌症。

Enpatoran (M5049) 是一种口服有效的TLR7 8选择性抑制剂，在HEK293 细胞中，IC50s 分别为 11.1 nM 和 24.1 nM。Enpatoran 可以阻断分子合成配体和天然内源性 RNA 配体。Enpatoran 在体内具有良好的药代动力学特性。Enpatoran 在先天性和适应性自身免疫阻断方面有研究的价值。

Azathioprine (BW 57-322) 是一种免疫抑制剂。

RVX-297 是口服具有活性的，对BD2有选择性的BET 高效抑制剂，作用于BRD2(BD2)、BRD3(BD2)、BRD4(BD2) 的IC50分别为 0.08、0.05、0.02 μM。它能够阻碍多种免疫细胞炎症基因的表达，对临床前模型急性炎症及自身免疫均有效。

IDO2-IN-1 是一种口服活性的强效IDO2抑制剂，其IC50为112 nM。该化合物适用于炎症性自身免疫研究。

Syk-IN-4 is a potent, selective, and orally bioavailable inhibitor of SYK, demonstrating an IC50 of 0.31 nM. It targets SYK, which has been identified as a potential therapeutic target for autoimmunity and hematological cancers[1].

P2X7-IN-2 TFA（化合物58）为P2X7受体抑制剂，以IC50为0.01 nM抑制IL-Iβ释放，适用于自身免疫病、炎症及心血管疾病研究。

Enpatoran (M5049) hydrochloride is a potent and orally active dual inhibitor of TLR7 8 with IC50 values of 11.1 nM and 24.1 nM in HEK293 cells, respectively. This compound specifically inhibits TLR7 and TLR8, while showing no activity against TLR3, TLR4, and TLR9. Enpatoran hydrochloride has the ability to block both synthetic molecule ligands and natural endogenous RNA ligands. Additionally, it demonstrates excellent pharmacokinetic properties in vivo. Enpatoran hydrochloride can be a valuable tool for studying and modulating both innate and adaptive autoimmunity. [1]

LTV-1 has the potential for autoimmunity treatment. LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC50 of 508 nM.

Myelin Oligodendrocyte Glycoprotein Peptide (35-55), mouse, rat (MOG (35-55)) 是中枢神经鞘的一个次要成分。它能诱导强效的 T 细胞和 B 细胞反应，同时是高度脑源性的。它能够引发复发缓解性神经系统疾病，伴有广泛的斑块样脱髓鞘。

P2X7-IN-2 是P2X7受体抑制剂。P2X7-IN-2 抑制 IL-Iβ 的释放，IC50值为 0.01 nM。P2X7-IN-2 可用于自身免疫病，炎症以及心血管疾病的研究。

HG-12-6 is a type II inhibitor of IRAK4. HG-12-6 shows preferential binding to unphosphorylated inactive IRAK4 (IC50: 165 nM). HG-12-6 can modulate IRAK4 activity in autoimmunity and inflammation.